tbuckley/cabot-search huggingface dataset:
Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreas cancer
Authors: R. Wilkowski, M. Thoma, C. Bruns, E. Duehmke, V. Heinemann
Journal: Journal of Clinical Oncology (2005)

4234 Objective: Primary resectability is expected in up to 20% of pancreas cancer patients (pts). While most pts relapse with distant metastasis, approximately 30% of patients show isolated local recurrence without evidence of distant failure The present analysis investigates the efficacy of chemoradiotherapy (CRT) in this particular patient group. Methods: Fourteen consecutive pancreas cancer pts presenting with isolated locoregional recurrence after surgical resection of pancreas cancer were included into the analysis. The median interval between primary surgery and diagnosis of local recurrence was 10.7 months (range, 2.0–19.3). Patients received 3-D conformal radiation with 45 Gy applied in 25 fractions with 1,8 Gy/day. In eight pts simultaneous chemotherapy was applied with a continuous infusion of 5-FU 350mg/m2, four of these pts additionally received gemcitabine 300mg/m2 as a 30-minute infusion on days 1, 15, and 29. Other six pts received a combination of cisplatin 30mg/m2 over one hour and gemcitabine 300mg/m2 over 30 minutes on treatment days 1,8, 22 and 29. Sequential chemotherapy with gemcitabine 1000mg/m2 and cisplatin 50mg/m2 was given to four pts before and 10 pts after chemoradiotherapy on days 1 and 15 (1 cycle before and 2 cycles after CRT). Results: In 13 of the 14 included pts radiotherapy was applied at the intended dose. While WHO grade 3–4 gastrointestinal toxicity was not reported, hematotoxicity was more pronounced. Grade 3 leukopenia occurred in two pts, and grade 3 thrombocytopenia was documented in four pts. One pt developed grade 4 leukocytopenia and thrombocytopenia, after which chemotherapy was discontinued. In ten evaluable pts 4 complete remissions, 4 partial remissions, and two stable diseases were noted. Median progression-free survival calculated from start of CRT was 14.7 months (range, 2.9–25.3 months). Five pts had another local relpase, while eight pts developed distant metastasis. Median overall survival from start of CRT was 17.0 months (27.2 months from initial diagnosis). Conclusion: The data provide a first indication that CRT is feasible and may be an effective treatment option in those pts who present with local failure after primary surgery of pancreatic cancer. No significant financial relationships to disclose.
Long-Term Prognosis of Renovascular Hypertension : Comparative Study in Operated and Non-operated Patients : Prognosis and Treatment of Renal Hypertension
Authors: Tadanao Takeda
Journal: Circulation (1975)

Long-term prognosis of renovascular hypertension has been studied in 56 patients. Twenty-nine patients underwent surgical treatment and 27 patients were not operated upon for various reason. Initial severity of hypertension in the operated group was nearly comparable to that of the non-operated group. Average of observation periods in each group is 5.8 and 5.9 years respectively, and the longest follow-up period has been up to 12 years. Hypertension cured or improved in 25 cases of the operated group. Antihypertensive therapy was effective in 7 of the medically treated patients. During the entire observation periods, 2 cases of the operated and 10 cases of the non-operated group died. Seven deaths of the non-operated group seemed to be causally related to hypertension. It is concluded that long-term prognosis of operated patients is significantly improved as compared with that of patients whose renovascular hypertension could not be treated surgically. Prevalence of aortitis (Takayasu's disease) as a .cause of renovascular hypertension is a particular problem in our series because extensive and complicated renovascular lesions may make surgical intervention difficult in some patients.
Identification of predictive and surrogate molecular markers for dasatinib in prostate cancer: Rationale for patient selection and efficacy monitoring
Authors: X. Wang, K. Reeves, R. Luo, S. Wu, L. Xu, M. Ayers, F. Lee, E. Clark, F. Huang
Journal: Journal of Clinical Oncology (2007)

3579 Background: Dasatinib is a potent, multi-targeted kinase inhibitor that was recently approved for treatment of chronic myelogenous leukemia resistant to imatinib. To aid its clinical development in prostate cancer, we used a panel of prostate cancer cell lines to identify molecular markers that could be used to predict sensitivity to dasatinib and to monitor its activity. Methods: Baseline gene expression profiles of 16 cell lines were used to identify predictive biomarkers based on the correlation of gene expression with in vitro sensitivity of cells to dasatinib. Selected cell lines were treated with dasatinib to identify surrogate biomarkers based upon changes in gene expression following dasatinib treatment. Results: We identified 174 genes whose baseline expression levels were highly correlated with sensitivity or resistance to dasatinib. These include cell lineage markers cytokeratin 5 (CK5), androgen receptor (AR), and prostate specific antigen (PSA). Our results indicate that “basal type” cell lines (those with high expression of CK5 and low expression of AR and PSA) are sensitive to dasatinib. Dasatinib treatment studies further identified genes whose expression levels were significantly modulated by the drug. Ten genes, including urokinase-type plasminogen activator (uPA), were not only significantly correlated with sensitivity to dasatinib but also reduced in their expression upon drug treatment. In addition, the down-regulation of uPA was specific to dasatinib and the effect was not seen in taxol-treated cells. The extent of down-regulation was correlated with the sensitivity of cell lines to dasatinib. EphA2, a specific kinase target of dasatinib, was identified as a biomarker common to prostate and breast cancers. Finally, the expression of 5 genes including CK5, AR, PSA, uPA and EphA2 in prostate tumors was examined and the dasatinib sensitivity signature was validated using a published data set derived from a clinical population. Conclusions: Candidate markers correlated with dasatinib sensitivity were identified. A five-gene model consisting of predictive markers as well as potential surrogate markers has been formulated and will be evaluated in ongoing dasatinib prostate cancer trials. No significant financial relationships to disclose.
Patterns of colorectal cancer care in the United States: 1990-2010.
Authors: Caitlin C. Murphy, Linda C Harlan, Jennifer Leigh Lund, Charles Lynch, Ann M. Geiger
Journal: Journal of Clinical Oncology (2015)

684 Background: Colorectal cancer (CRC) incidence and mortality have declined in the U.S. over the past two decades. Much of the decline can be attributed to screening and advances in treatment. Few studies have evaluated the extent to which recommended therapies have been adopted in community settings and temporal changes in patterns of care. Methods: Patients diagnosed with stages II and III CRC were randomly sampled from the population-based Surveillance, Epidemiology, and End Results (SEER) program in 1990-91, 1995, 2000, 2005, and 2010 (n=7,056). Treatment data were obtained through medical record review and physician verification. We described the receipt of adjuvant chemotherapy among colon cancer patients and preoperative or postoperative radiation therapy among rectal cancer patients. Log-binomial regression was used to examine factors associated with receipt of therapy. Results: Receipt of adjuvant chemotherapy increased among stages II and III colon cancer patients from 1990 (stage II: 22%, stage III: 55%) to 2005 (stage II: 32%, stage III: 72%) and decreased in 2010 (stage II: 29%, stage III: 65%). Chemotherapy regimens changed over time; there was an increase in the use of capecitabine (3% in 2000 to 24% in 2010) and oxaliplatin (6% in 2000 to 79% in 2010). Stage III colon cancer patients who were older (75-79 years: RR 0.82, 95% CI 0.72, 0.94; ≥80 years: RR 0.36, 95% CI 0.27, 0.49) or had a comorbidity score ≥ 2 (RR 0.54, 95% CI 0.34, 0.86) were less likely to receive adjuvant chemotherapy. Receipt of radiation therapy among stages II and III rectal cancer patients increased across all study years from 46% to 66%, with a shift toward preoperative therapy in 2005. From 2005 to 2010, receipt of neoadjuvant chemoradiation followed by surgery and postoperative chemotherapy nearly doubled (11% in 2005 to 21% in 2010). Increasing age (75-79 years: RR 0.60, 95% CI 0.48, 0.75; ≥80 years: RR 0.34, 95% CI 0.25, 0.45) was associated with lower chemoradiation use in rectal cancer. Conclusions: Our findings demonstrate increased adoption of adjuvant therapies for both colon and rectal cancer patients and differences in therapy receipt by age, comorbidity, and diagnosis year. Improved receipt of adjuvant therapies in the community may further reduce CRC mortality.
Chemotherapy in advanced gastric carcinoma.
Authors: A Adenis, J Bonneterre
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.11.2077 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 1941068 Chemotherapy in advanced gastric carcinoma. A AdenisxA AdenisSearch for articles by this author , J BonneterrexJ BonneterreSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.11.2077 PDF "Chemotherapy in advanced gastric carcinoma.." Journal of Clinical Oncology, 9(11), pp. 2077–2078© 1991 by American Society of Clinical Oncology
Desmoplastic Small Round Cell Tumor (Dsrct) in Adult Population: Retrospective Analysis
Authors: T.S. Correa, A.M.G. Andrade, D.A. Toloi, C. Venchiarutti, V.P. Camargo, M.S. Goncalves, P.M. Hoff
Journal: Annals of Oncology (2014)
Salmonella meningitis and septicaemia in an non-immunocompromised adult, associated with a cluster of Salmonella Enteritidis PT 14b, Ireland, November 2009
Authors: C O ÓhAiseadha, Ó M Dunne, F Desmond, M O’Connor
Journal: Eurosurveillance (2010)

We report a fatal case of meningitis caused by Salmonella Enteritidis phage type 14b in a middle-aged man who had no history or findings to suggest he was immunocompromised. To our knowledge, this is the first reported case of Salmonella meningitis in an adult in Ireland, and the first case of meningitis in an adult caused by phage type 14b. This case was associated with a nationwide cluster of salmonellosis which is still under investigation at the time of writing.
Randomized phase II study of thalidomide for the control of delayed chemotherapy-induced nausea and vomiting
Authors: L. Yun-Peng, Z. Jingdong, T. Yuee, J. Bo, Y. Ping, Z. Mingfang, S. Jing, Z. Lingyun, L. Zhi
Journal: Journal of Clinical Oncology (2008)

9614 Background: The aim of the study is to evaluate the efficacy of thalidomide for treatment of delayed chemotherapy-induced nausea and vomiting (CINV) with emetogenic chemotherapy. Methods: Chemotherapy-naive patients with histological confirmed malignancies were randomized divided into 2 groups: A-B group (A, ramosetron 0.3mg IV plus dexamethasone 10mg IV or PO on day 1, was given in the first cycle and B, ramosetron plus dexamethasone on day1 plus thalidomide 150 mg orally twice a day on day 1 through 5, in the second cycle) and B-A group (those drugs were given in the reverse sequence). The primary end point was the efficacy of thalidomide in controlling delayed CINV. The secondary end point was the safety of thalidomide. The descriptive statistics was used. Fertile patients must use effective contraception. Results: Of 43 patients enrolled between October, 2006 to January, 2007, 41 patients (95%) were assessable. Median age was 53 years (range 43–69). Chemotherapy regimen included CDDP-based regimen(CDDP≥70 mg/m2, d1), CEF(cyclophosphamide 600mg/m2, d1, epirubicin 60–80mg/m2, d1, plus 5-fluorouracil 600mg/m2, d1, Q 3 W),CE(cyclophosphamide 600mg/m2, d1, epirubicin 60–80mg/m2, d1, Q 3 W) and mFOFOX6 (oxaliplatin 100–130mg/m2, IV, over 2 hours, d1, leucovorin 200mg/m2, IV, over 2 hours, d1, followed by 46-hour 2,800mg/m2 5-fluorouracil,IV, Q 3 W). Pt characteristics (%) were: male/female 41.5/58.5; ECOG PS 0/1 51.2/48.8; lung cancer/gastrointestinal cancer/breast cancer/other 14.6/70.7/9.8/4.9; CDDP-based regimen/CEF/CE/mFOFOX6 19.5/7.3/2.4/70.7, Group A-B/ B- A 53.7/46.3. Complete response of delayed nausea and emesison on day 2 through 5 were 48.7% of group B vs 17.1% of group A (p=0.002) and 78.0% of group B vs 56.1% of group A (p=0.034), respectively. Adverse effects were mostly mild to moderate, and no grade 4 toxicities in any treatment cycle. Sedation were more common in group B (31.7% vs 0%, p=0.000 on day 1; 36.59% vs 4.88%, p=0.000 on day 2; 29.27% vs 2.44%, p=0.001 on day 3; 24.39% vs 2.44%, p=0.004 on day 4). While disappetite were more common in group A (68.29% vs 36.59%, p=0.004 on day 3; 63.41% vs 41.46%, p=0.047 on day 4). Conclusions: This is the first report to demonstrate that thalidomide is safe and effective in controlling delayed CINV. No significant financial relationships to disclose.
Mitochondrial Reprogramming Regulates Breast Cancer Progression
Authors: Anbarasu Kannan, Robert B. Wells, Subramaniam Sivakumar, Satoshi Komatsu, Karan P. Singh, Buka Samten, Julie V. Philley, Edward R. Sauter, Mitsuo Ikebe, Steven Idell, Sudeep Gupta, Santanu Dasgupta
Journal: Clinical Cancer Research (2016)

The goal of this study was to understand the role of altered mitochondrial function in breast cancer progression and determine the potential of the molecular alteration signature in developing exosome-based biomarkers.This study was designed to characterize the critical components regulating mitochondrial function in breast tumorigenesis. Experiments were conducted to assess the potential of these molecules for exosome-based biomarker development.We observed a remarkable reduction in spontaneous metastases through the interplay in mitochondria by SH3GL2, vesicular endocytosis-associated protein and MFN2, an important regulator of mitochondrial fusion. Following its overexpression in breast cancer cells, SH3GL2 translocated to mitochondria and induced the production of superoxide and release of cytochrome C from mitochondria to the cytoplasm. These molecular changes were accompanied by decreased lung and liver metastases and primary tumor growth. SH3GL2 depletion reversed the above phenotypic and associated molecular changes in nontumorigenic and tumorigenic breast epithelial cells. Loss of SH3GL2 and MFN2 expression was evident in primary human breast cancer tissues and their positive lymph nodes, which was associated with disease progression. SH3GL2 and MFN2 expression was detected in sera exosomes of normal healthy women, but barely detectable in the majority of the women with breast cancer exhibiting SH3GL2 and MFN2 loss in their primary tumors.This study identified a new mitochondria reprogramming pathway influencing breast cancer progression through SH3GL2 and MFN2. These proteins were frequently lost in breast cancer, which was traceable in the circulating exosomes. Clin Cancer Res; 22(13); 3348-60. ©2016 AACR.
Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal carcinoma: Preliminary results
Authors: A. Salud, V. Alonso, J. Lambea, J. Valencia, M. Mira, S. Polo, P. Escudero, E. Sierra, J. Lao
Journal: Journal of Clinical Oncology (2006)

13543 Background: Preoperative chemoradiotherapy has shown to improve local control and sphincter preservation with decreased acute toxicity compared with postoperative treatment in locally advanced rectal carcinoma. The primary endpoint of this phase II trial was pathologic tumor response. Secondary endpoints were sphincter preservation and toxicity. Methods: Inclusion criteria: rectal adenocarcinoma &lt;12 cms from anal verge, clinical stage T3–4 and/or N+, adequate renal, hematological and liver function. Planned sample for this trial was 43 patients. Treatment scheme: pelvic radiotherapy (50.4 Gy/28 fractions) and chemotherapy: Capecitabine 825 mg/m 2 /12 hours on days 1–5 + Oxaliplatin 50 mg/m 2 on day 1 every week (weeks 1–6). Surgery with TME was performed between 6–8 weeks after the end of the treatment. Adjuvant chemotherapy was administered after surgery according each center criteria. Results: 37 patients have been recruited between February and December 2005. 26 male/11 female. Median age 70 years (range 38–79). Clinical stage (determined by EUS+CT or RMI): cT2 1p/cT3 33p/cT4 3p/cN+ 27p. Tumor location (from anal verge): ≤ 5 cm in 15p, &gt;5 cm in 22p. Surgery (performed in 26 patients) consisted of low anterior resection in 13p and abdominal-perineal resection in 13p. Tumor downstaging was observed in 17p (65%), 20 (77%) had negative lymph nodes, including 6p with complete pathological response (23%) and four with only microfoci of tumor remaining (15%). Main adverse effects (NCI-CTC): diarrhea G3–4 19%, sensitive peripheral neurotoxicity G1 38%, skin G2 11%, nausea/vomiting G2 11%, fatigue/malaise G3 4%, neutropenia G3 7%. Conclusions: Preliminary results show that preoperative chemoradiotherapy with capecitabine and oxaliplatin is a well tolerated regimen for locally advanced operable rectal cancer leading to a high probability of tumor downstaging. No significant financial relationships to disclose.
Abstract 1912: Reduction of microRNA-21 by vitamin D compounds during ductal carcinoma in situ transition to invasive ductal carcinoma
Authors: Joseph Wahler, Larry C. Cheng, Hubert Maehr, Milan Uskokovic, Nanjoo Suh
Journal: Cancer Research (2015)

Abstract MicroRNAs (miRNAs) are small RNA molecules of approximately 22 nucleotides in lengths that can negatively control target gene expression post-transcriptionally. There are currently more than one hundred known human miRNAs. miRNAs have been shown to play an important role in the development and progression of various types of cancer. In breast cancer, ductal carcinoma in situ (DCIS) is an early non-invasive precursor, which is known to progress to invasive ductal carcinoma (IDC) if left untreated. The involvement of miRNAs in the breast cancer progression from DCIS to IDC is still not well understood, and potential regulation of miRNAs by vitamin D compounds during the progression has not been tested. We have previously reported that a novel Gemini vitamin D analog, 1α,25-dihydroxy-20R-21(3-hydroxy-3-deuteromethyl-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-cholecalciferol (BXL0124), inhibits the progression of DCIS to IDC in vivo. To identify miRNAs that could potentially be involved in DCIS progression to IDC, we utilized the MCF10DCIS.com xenograft tumors. MCF10DCIS.com cells (10^6 cells/mouse) were injected subcutaneously into the rear flanks of nu/nu mice. The mice were then treated with BXL0124 (0.1 μg/kg) for 5 weeks. The critical DCIS to IDC transition occurred between weeks 3 and 4 in the in vivo lesions, and several microRNAs were assessed with respect to the DCIS to IDC transition at weeks 3 and 4. Among many miRNAs analyzed, miR-21, miR-24, and miR-140 were up-regulated in IDC lesions compared to DCIS lesions, whereas no marked changes were observed with respect to miR-200c, miR-let-7a, miR-26a, miR-34a, and miR-182. One of the miRNAs identified miR-21, is a well-known oncomir and overexpressed in breast carcinoma, mediating cell survival, proliferation, and metastasis. The increased expression of miR-21 was significant when DCIS lesions progressed to IDC, and this effect was diminished by the treatment with Gemini vitamin D, BXL0124, at week 4. In conclusion, vitamin D compounds reduce the levels of miR-21 during DCIS transition to IDC, potentially contributing to its preventive effects in breast cancer progression. Further investigation of the mechanisms of action by which vitamin D compounds regulate miR-21 should be considered. (This work was supported in part by the National Institutes of Health National Cancer Institute R01-CA127645 and the National Institute of Environmental Health Sciences Grant ES005022). Citation Format: Joseph Wahler, Larry C. Cheng, Hubert Maehr, Milan Uskokovic, Nanjoo Suh. Reduction of microRNA-21 by vitamin D compounds during ductal carcinoma in situ transition to invasive ductal carcinoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1912. doi:10.1158/1538-7445.AM2015-1912
Does it still make sense to develop a declarative memory theory of hippocampal function?
Authors: J. N. P. Rawlins, R. M. J. Deacon, B. K. Yee, H. J. Cassaday
Journal: Behavioral and Brain Sciences (1994)

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Incidence of acute kidney injury in cancer patients: A population-based cohort study in Denmark
Authors: C. F. Christiansen, M. B. Johansen, S. Christensen, W. Langeberg, J. P. Fryzek, H. Toft Sørensen
Journal: Journal of Clinical Oncology (2009)

9570 Background: Although cancer patients may be at increased risk for acute kidney injury (AKI), which could then reduce their likelihood of receiving optimal therapeutic management and supportive care, the occurrence of AKI among newly diagnosed cancer patients has not been well-described. Therefore, we examined the incidence of AKI within the first year after cancer diagnosis to estimate the magnitude of this risk and better understand which patients are at greatest risk. Methods: Using the population-based Danish Cancer Registry, we conducted a retrospective cohort study of 4,427 men and women from North Jutland, Denmark (population 500,000) diagnosed with cancer from 2002 to 2003 (non-melanoma skin cancer excluded). AKI was defined according to the Risk/ Injury/ Failure/ Loss/ End-stage-renal-disease (RIFLE) criteria. We included Risk or worse: at least a 1.5 times increase in serum creatinine (sCr) from baseline. SCr levels were obtained from the Regional Laboratory Database, which collects all biochemical analyses for hospital laboratories. Baseline sCr was defined as the lowest sCr in the year before cancer diagnosis. We compared this value to the highest sCr on record during the first year following cancer diagnosis to identify those who experienced an AKI. Results: Median age for the cohort was 68.6 years, 50.9% were men, and the most common cancer sites were lung (14.2%), breast (13.7%), prostate (9.8%), colon (9.6%), rectum (5.1%), and bladder (6.3%). During the first year, 973 (22.0%) members of the cohort experienced an AKI, corresponding to an overall incidence rate of 326 per 1,000 person-years (95% confidence interval (CI) 306–347). Incidence was highest among patients aged 80 years or older (531 per 1,000 person-years, 95% CI 464–606) and in those with cancer of the liver (1,221, 95%CI 676–2,205), pancreas (1,472, 95%CI 1,130–1,917), or kidney (1,254, 95%CI 974–1,616), or with multiple myeloma (855, 95%CI 538–1,356). Conclusions: To protect against AKI, we must first identify those at risk. Our study showed that over 20% of cancer patients may experience acute kidney injury in the first year after diagnosis. Older patients and those with cancer of the liver, pancreas, or kidney, or with multiple myeloma are especially at risk for AKI. [Table: see text]